Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

被引:0
作者
M. Tanioka
H. Nokihara
N. Yamamoto
Y. Yamada
K. Yamada
Y. Goto
T. Fujimoto
R. Sekiguchi
K. Uenaka
S. Callies
T. Tamura
机构
[1] National Cancer Center Hospital,Division of Internal Medicine
[2] Eli Lilly Japan K.K.,undefined
[3] Eli Lilly and Company,undefined
[4] Erl Wood Manor,undefined
来源
Cancer Chemotherapy and Pharmacology | 2011年 / 68卷
关键词
Antisense oligonucleotide; Pharmacokinetics; Phase I; Survivin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:505 / 511
页数:6
相关论文
共 138 条
[1]  
Ambrosini G(1997)A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3 917-921
[2]  
Adida C(2003)Validating survivin as a cancer therapeutic target Nat Rev Cancer 3 46-54
[3]  
Altieri DC(2009)Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: correlation with clinicopathologic features and patient survival Cancer Epidemiol Biomarkers Prev 18 417-423
[4]  
Altieri DC(2003)Targeting survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells Cell Cycle 2 488-493
[5]  
Shen YC(2004)Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin’s lymphoma Leukemia 18 616-623
[6]  
Hu FC(1999)Pleiotropic cell-division defects and apoptosis induced by interference with survivin function Nat Cell Biol 1 461-466
[7]  
Jeng YM(2003)Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species Drug Metab Dispos 31 1419-1428
[8]  
Chang YT(2005)Predicting drug response and toxicity based on gene polymorphisms Crit Rev Oncol Hematol 54 171-196
[9]  
Lin ZZ(2007)Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis J Hepatol 46 1104-1110
[10]  
Chang MC(2004)Toxicology of antisense therapeutics Toxicol Appl Pharmacol 201 66-83